Drug recall · January 12, 2022
EQUALINE aller-ease fexofenadine hydrochloride tablets recall
Why: Failed Impurities/Degradation Specifications; Out of specification result obtained for impurity A during stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
EQUALINE aller-ease fexofenadine hydrochloride tablets, 180 mg, 24 HR, packaged as a) 15 count bottle, NDC 41163-571-22, UPC 0 41163 48067 4; b) 70 tablets per bottle, NDC 41163-571-01, UPC 0 41163 49847 1; Made in the Czech Republic, Distributed by: UNFI Providence, RI 02908.
- Lots / codes
Lot # a)0HE2530 Exp 12/31/2021, 0KE2980 EXP 02/28/2022 b)0FR0461 Exp 2/28/2022
- Quantity
- 55,032 units
- Company
- Perrigo Company PLC, Allegan, MI
- Distribution
- Nationwide in the USA
- Initiated
- July 27, 2021 · Voluntary: Firm initiated
- Classified
- January 5, 2022
- Reported
- January 12, 2022
- Ended
- November 8, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Fexofenadine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.